Cell Regeneration·2 hLiver regeneration governed by zonated PIEZO1 mechanotransductionExperiments in animalsMechanismsPaper
Advances in Therapy·23 SepComparative Effectiveness of Once-Weekly Semaglutide Versus Sulfonylureas, DPP4 Inhibitors, and Thiazolidinediones in Patients with Type 2 Diabetes and Chronic Kidney DiseaseCohort study in peopleSemaglutidePaper
Diabetes Therapy·17 SepComparing Cardiovascular Outcomes in New Users of Oral Semaglutide Versus Other Noninsulin Glucose-Lowering Therapies Among Adults with Type 2 Diabetes and Atherosclerotic Cardiovascular DiseaseCohort study of 28,639 peopleSemaglutidePaper
European Journal of Preventive Cardiology·16 SepFlow-Mediated Dilation in Competitive Athletes: Non-linear Associations and Haemodynamic CharacteristicsReviewPopulationsPaper
NPJ Cardiovascular Health·12 AugPeriodontal disease and cardiovascular events: mechanisms, biomarkers, and clinical translationReviewMechanismsPaper
ADA Scientific Sessions 2026 Abstract·6 JunHbA1c and Weight Outcomes among Adults with Type 2 Diabetes on 25 mg Oral Semaglutide Previously Treated with Metformin Only: A Post hoc Analysis from PIONEER PLUSTrial in peopleInterventionsPaper
ADA Scientific Sessions 2026 Abstract·5 JunComparing Major Adverse Kidney Events (MAKE) among New Users of Oral Semaglutide (SEMA) vs. Select Oral Antidiabetic Medications (ADMs) among U.S. Adults with Type 2 Diabetes (T2D) and Chronic Kidney Disease (CKD)Study in peopleInterventionsPaper
AHA Scientific Sessions 2025 Abstract·3 NovPatients with Dementia admitted for Heart Failure Demonstrate Worse Clinical and Patient-centered OutcomesStudy in peoplePopulationsPaper
AHA Scientific Sessions 2025 Abstract·3 NovPerformance of the Diabetes Outcomes Model in the United States (DOMUS) in a Large, Contemporary US Claims DatasetStudy in peopleBiomarkersPaper
AHA Scientific Sessions 2025 Abstract·3 NovComparing Cardiovascular Outcomes in New Users of Oral Semaglutide Versus Other Noninsulin Glucose-Lowering TherapiesStudy in peopleInterventionsPaper
ADA Scientific Sessions 2025 Abstract·13 JunPrevalence and Factors for Treatment Failure with Sodium–Glucose Cotransporter 2 Inhibitor (SGLT2i) in U.S. Adults with Type 2 Diabetes (T2D)Study in peoplePopulationsPaper
ADA Scientific Sessions 2025 Abstract·13 JunChanges in Clinical Measures in U.S. Adults with Type 2 Diabetes (T2D) and Chronic Kidney Disease (CKD) Who Received Once-Weekly (OW) SemaglutideStudy in peopleInterventionsPaper
ADA Scientific Sessions 2025 Abstract·13 JunReal-World Impact of Oral Semaglutide (SEMA) vs. DPP-4 Inhibitors on Weight, BMI, and HbA1c Outcomes in Type 2 Diabetes (T2D)—An Observational Study (PAUSE)Study in peopleInterventionsPaper
ADA Scientific Sessions 2025 Abstract·13 JunChanges in Clinical Measures among U.S. Adults with Type 2 Diabetes (T2D) and Chronic Kidney Disease (CKD) Receiving Once-Weekly Semaglutide (sema OW) vs. Oral Antidiabetic Medications (ADMs)Study in peopleInterventionsPaper
ADA Scientific Sessions 2025 Abstract·13 JunMacrovascular and Microvascular Complications in Medicare Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease From 2006–2021—Incidence Stratified by Sex, Age, and Race/EthnicityStudy in peoplePopulationsPaper